Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 1, 2008, Pages 95-105

  Nutescu, Edith A ^a   Pater, Karen Steinmetz ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cost effectiveness; Low molecular weight heparin; Non ST segment elevation acute coronary syndrome; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; SIMVASTATIN; STREPTOKINASE; THROMBIN INHIBITOR; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG USE; ECONOMIC EVALUATION; HEALTH ECONOMICS; HEART CATHETERIZATION; HEART INFARCTION; HOSPITALIZATION COST; HUMAN; MONOTHERAPY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; ENOXAPARIN; EXPERT TESTIMONY; HEALTH CARE COSTS; HUMANS; MYOCARDIAL ISCHEMIA;

EID: 39049154252     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.1.95     Document Type: Review

References (51)

1. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056-63
2. Kochanek KD, Smith BL. Deaths: preliminary data for 2002. Natl Vital Stat Rep 2004;52:1-47
3. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-40
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106:1893-900
5. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87
6. Théroux P, Ouimer H, Mccans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11
7. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated hcparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337:447-52
8. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996;276:811-15
9. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17
10. Melandri G, Semprini F, Cervi V, et al. Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 1993;72:450-4
11. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-5
12. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005;106:2710-15
13. Budaj A, Brieger D, Steg PG, et al. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2003;146:999-1006
14. Samama MM, Bara L, Gerotziafas GT. Mechanism fbr the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994;24:105-17
15. Antman EM, Mccabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100:15593-601
16. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-68
17. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAX.I.S (FRAxiriparine in Ischaemic Syndrome). Eur Heart J 1999;20:1553-62
18. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin. Am Heart J 2002;144:470-7
19. Goodman SG, Fitchett D. Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-scgment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107:238-44
20. Blazing MA, De Lemos JA, White HD, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;292:55-64
21. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated. heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54
22. Michalis LK, Katsouras CS, papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003;146:304-10
23. Katsouras C, Michalis LK, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months. Am Heart J 2005;150:385-91
24. Medical Economics: Unfractionated heparin (UFH) and Lovenox average wholesaleprice (AWP) comparison based on an average of 3 UFH suppliers' and Lovenox AWPs. In: Red Book 2003 Drug Topics: The Pharmacist's Trusted Companion for More Than a Century; Montvale, NJ: Thomson Healthcare; 2003. p. 362-410
25. Levine GN, Lincoff AM, Ferguson JJ, et al. Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. Catheter Cardiovasc Interv 2005;66:149-57
26. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004;292:2096-104
27. Fox KA, Antman EM, Cohen M, et al. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/ non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol 2002;90:477-82
28. Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enomaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003;41:20-25
29. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-17
30. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89-96
31. An international randomized trial comparing four thrombolytic strategies fbr acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673-82
32. Cohen M, Mahaffey KW, Pieper K, et al. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated. heparin in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006;48:1346-54
33. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-54
34. Mark DB, Cowper PA. Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998;97:1702-7
35. O'Brien BJ, Willan A, Blackhouse G, et al. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000;139:423-9
36. Balen RM, Marra CA, Zed PJ, et al. Cost-effectiveness analysis of cnoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective. Pharmacoeconomics 1999;16(5 Pt 2):533-42
37. Fox KA. Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998;5:92-105
38. Bosanquet N, Fox KA. Longer term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: One-year data. Br J Cardiol 2001;8:36-37
39. Brosa M, Rubio-Terres C, Farr I, et al. Cost-effectivenss analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome. Pharmacoeconomics 2002;20:979-87
40. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J Am Coll Cardiol 1997;29:1474-82
41. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-8
42. Mahaffey KW. Cohen M, Garg J, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005;294:2594-600
43. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007;154:3-11
44. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000;36:693-8
45. White HD, Kleiman NS, Mahaffey KW. et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006;152:1042-50
46. Ewen E, Weintraub WS, Zhao L, et al. Cost and cost-effectiveness of intravenous enoxaparin versus unfractionated heparin in elective pcrcutancous coronary intervention: Results from the STEEPLE trial. American Heart Association Annual Meeting; 2006; Chicago, IL, USA; [Abstract 3858]
47. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigatos, Yusuf S, Mehta SR, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Mcd 2006;354:1464-76
48. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004;44:1792-800
49. Lincoff AM, Bird JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63
50. Stone GW, Mclaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16
51. Pinto DS, Stone GW, Mclaurin BT, et al. In-hospital costs for patients managed with an early invasive strategy for NSTEMI/ACS. Preliminary results from the ACUTTY study. Transcatheter Cardiovascular Therapeutics Meeting; 2006 Washington, DC, USA, [Abstract 498]